Infuse is an implantable device that uses a biological agent to stimulate bone growth to treat degenerative disc disease of the spine.
Infuse has been implanted in more than 1 million patients, but approximately 85 percent of the time it was used off-label, according to a Milwaukee Journal Sentinel report.
Nashville-based Vanderbilt University orthopedic surgeon Dan Spengler, MD, said in the report many of the patients likely experienced excess bone growth following an off-label surgery.
Medtronic spokeswoman Cindy Resman said in the report Medtronic will “vigorously defend [Infuse] in court.”
More Articles on Medtronic:
Johnson & Johnson, Medtronic Enter Pilot Program for More Efficient Supply Chain Ordering
Medtronic Receives FDA 510(k) Clearance for Reveal LINQ Insertable Cardiac Monitor
World’s Smallest Pacemaker by Medtronic Implanted in Clinical Trial
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
